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Message from NPCR Leadership 
November 29, 2016 
We are pleased to share data from the National Program of Cancer Registries (NPCR) in this 
new format with the public health research community. This will be the first time a cancer 
dataset this large and representative will be publicly and freely available to researchers.  
Conducting public health surveillance is a core function of CDC and one the agency is proud to 
lead. We invest important resources into various disease surveillance systems to help protect our 
nation against dangerous health threats, including cancer. NPCR is one of the most 
comprehensive and complex of CDC’s disease surveillance systems and involves compiling and 
disseminating information on over 1.6 million cancers annually, representing 96% of all 
invasive cancers diagnosed in the United States. When NPCR data are combined with the 
National Cancer Institute’s Surveillance, Epidemiology and End Results (SEER) data, 100% US 
population coverage is achieved.  
NPCR was first authorized by the US Congress in 1992. Though CDC cooperative agreements, 
the program currently supports 45 states, the District of Columbia, Puerto Rico, and the US 
Pacific Island Jurisdictions. Many of our supported partners have been submitting data to CDC 
since the mid-1990’s.  
We encourage researchers to use our data to help inform scientific inquiries, programs, and 
policies. This data source is a product of tremendous efforts by reporting facility staff, cancer 
registrars, central cancer registry staff, and CDC NPCR staff and contractors. Most importantly, 
however, these data represent individuals who have been affected by a cancer diagnosis. 
Through use of this dataset, researchers can continue to have a positive impact on 
comprehensive cancer prevention and control and the care and quality of lives for those 
diagnosed with cancer.  
Sincerely, 
A Blythe Ryerson, MPH, PhD 
Lead Epidemiologist, Cancer Surveillance Branch 
Division of Cancer Prevention and Control 
National Center for Chronic Disease Prevention and Health Promotion  
Overview of CDC’s National Program of Cancer Registries  
The National Program of Cancer Registries (NPCR), administered by the Centers for Disease Control and 
Prevention (CDC), was established by Congress in 1992. Through cooperative agreements, NPCR 
supports central cancer registries in 45 states, the District of Columbia, Puerto Rico, and the U.S. Pacific 
Island Jurisdictions (see map below). These central cancer registries represent 96% of the United States 
population (2013), including 96% of whites, 98% of African Americans, 96% of Hispanics, 93% of 
American Indians and Alaska Natives (AI/AN), and 93% of Asians and Pacific Islanders (A/PI).  
The cancer registries routinely collect data on patient demographics, primary tumor site, tumor 
morphology, stage at diagnosis, first course of treatment, and outcomes. Multiple medical facilities, such 
as hospitals, doctor’s offices, pathology laboratories, and other treatment centers send demographic and 
clinical information related to persons with incident cancer to the central cancer registry, where the 
information is consolidated. Every year since 2000, the NPCR central cancer registries have been 
submitting relevant demographic and clinical information about each diagnosed cancer case to CDC. 
None of the information submitted to CDC contains personally identifiable information about 
individual patients. 
CDC works closely with a variety of partners to deliver and manage this cancer surveillance system. One 
of CDC’s most critical partners is the National Cancer Institute (NCI), which funds the Surveillance, 
Epidemiology, and End Results (SEER) Program. Together, CDC’s NPCR and NCI’s SEER programs 
cover the entire United States population. These combined data are the official source of federal statistics 
on cancer incidence and are presented in the United States Cancer Statistics (USCS) Incidence and 
Mortality Web-based Report.  
This national coverage enables researchers, clinicians, policy makers, public health professionals, and 
members of the public to monitor the burden of cancer, evaluate the successes of programs, and identify 
additional needs for cancer prevention and control efforts at national, state, and local levels. At NCI’s 
request, data from the five states supported solely by the SEER program are not included in this 
database.  
 
Figure 1. Central cancer registry programs funded by NPCR 
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NPCR Data Collection, Submission, Quality, and Coverage  
The most current data come from the 2015 November NPCR submission, which covers incident cancer 
cases diagnosed in 2001 through 2013. Each year, NPCR-funded central cancer registries submit to CDC 
data on cancer diagnosed during the most recent year. In addition, data from previous years are updated 
with information from the newly submitted records. NPCR allows an interval of 23 months after the close 
of the diagnosis year for submission (by November 30, 2015 for 2013 data) to ensure case completeness 
and high quality. CDC supports the data collection and quality standards from the North American 
Association of Central Cancer Registries (NAACCR) consensus documents. During data collection, CDC 
also applies additional rigorous quality control edits, data completeness evaluations, and data quality 
assessments on all NPCR data. For a registry’s data to be included in the NPCR public research data file, 
they must have met the quality and completeness criteria for publication in United States Cancer 
Statistics (USCS): 
• Case ascertainment greater than or equal to 90% (with a margin of error of plus or minus 5%). 
• 5% or fewer cases are ascertained solely on the basis of a death certificate. 
• 3% or fewer cases are missing information on sex. 
• 3% or fewer cases are missing information on age. 
• 5% or fewer cases are missing information on race. 
• 97% or more of the registry’s records passed a set of single-field and interfield computerized 
edits.  
NPCR 2001–2013 Public Use Research Database 
Two NPCR public use databases are available for researchers: the 2001–2013 database and the 2006–
2013 database. This data standards document is specific to the 2001–2013 database. 
The 2001–2013 database includes race and ethnicity variables, while the 2006–2013 database does not. 
The 2006–2013 database includes Puerto Rico data, while the 2001–2013 database does not. 
• The 2001–2013 database’s population denominators are race-specific, ethnicity-specific, and sex-
specific county population estimates from the U.S. Census, modified by SEER and aggregated to the 
state and national levels. 
• The 2006–2013 database’s population denominators are sex-specific, are from the 2010 U.S. Census, 
and are not available by race or ethnicity. 
Table 1 lists the population coverage by diagnosis year for the NPCR public research data.  
For more detail on data availability by central cancer registry from 2001–2013, see Table 2 below.  
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Table 1. U.S. population coverage, NPCR 2015 submission 2001–2013 public use research database 
Diagnosis year(s) a 
% U.S. population 

















a For the calculated percent population coverage for a range of years not shown 
in Table 1 (e.g., 2007–2012), please send a request to: npcrdata@cdc.gov. 
b The most recently submitted 10 years of data. 
c The most recently submitted 5 years of data. 
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Table 2. Central cancer registry data included in the 2001–2013 public use research databasea 
 
Registry 
Year of Diagnosis 
2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 
Alabama              
Alaska              
Arizona              
Arkansas              
California              
Colorado              
Delaware              
District of Columbia  NA            
Florida              
Georgia              
Idaho              
Illinois              
Indiana              
Kansas              
Kentucky              
Louisiana              
Maine              
Maryland              
Massachusetts              
Michigan              
Minnesota              
Mississippi NS NA            
Missouri              
Montana              
Nebraska              
Nevada           NA NA NA 
New Hampshire              
New Jersey              
New York              
North Carolina              
North Dakota              
Ohio              
Oklahoma              
Oregon              
Pennsylvania              
Rhode Island              
South Carolina              
South Dakota              
Tennessee NA NA            
Texas              
Vermont              
Virginia NA NA            
Washington              
West Virginia              
Wisconsin              
Wyoming              
Shaded box: Data meet the United States Cancer Statistics (USCS) publication criteria and are available in the 2001-2013 public 
use research database. 
NS: Data were not submitted and are not available in the 2001-2013 public use research database. 
NA: Data did not meet USCS quality and completeness criteria for publication and are not available in the 2001-2013 public use 
research database. 
a Puerto Rico and U.S. Pacific Island Jurisdiction data are not included in the 2001–2013 public use research database. Regardless 
of data completeness or quality, at NCI’s request, data from states funded solely through the SEER program (Connecticut, Hawaii, 
Iowa, New Mexico, and Utah) are not included in this database. 
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Variable List 
Table 3 shows all the variables available in the 2001-2013 public use research database.  
Table 3. Variables in the 2001–2013 NPCR Public Use Research Database 
SEER*Stat Category SEER*Stat Variable Name 
Age at Diagnosis Age recode with <1 year olds  
Race, Sex, Year Dx, Registry, 
County 
Sex 
Year of diagnosis 








Origin recode NHIA (Hispanic, Non-Hisp) 
Site and Morphology Primary Site – labeled  
Histologic Type ICD-O-3 
Grade  
Diagnostic confirmation  
Site recode ICD-O-3/WHO 2008 
ICCC site recode ICD-O-3/WHO 2008 
ICCC site rec extended ICD-O-3/WHO 2008 
 AYA site recode/WHO 2008 
 Lymphoma subtype recode/WHO 2008 
 Behavior recode for analysis derived/WHO2008 
Stage – LRD [Summary and Historic] Merged Summary Stage 2000 
Extent of Disease – CS Laterality 
Multiple Primary Fields Sequence number - central 
Dates  Month of diagnosis 
Other Type of Reporting Source  
Abbreviations used in variable names 
Addr  Address 
AYA  Adolescent and young adult 
CS  Collaborative stage 
Dx  Diagnosis 
ICCC  International Classification of Childhood Cancer 
ICD-O-3  International Classification of Diseases for Oncology, Third Edition 
LRD  Local, regional, distant 
NHIA  NAACCR Hispanic identification algorithm  
SS  Summary stage  
USCS  United States Cancer Statistics 
WHO  World Health Organization 
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Data Citation 
Please use these standard citations for tables and figures when presented in presentations or 
publications.  
• For population coverage: Data are from population-based registries that participate in the National 
Program of Cancer Registries and meet high-quality data criteria. These registries cover approximately 
[XX]% of the U.S. population.  
• For age-adjusted rates: Rates are per 100,000 persons and are age-adjusted to the 2000 U.S. 
standard population (19 age groups – Census P25–1130). 
• For the 2001–2013 database: National Program of Cancer Registries SEER*Stat Database: NPCR 
Incidence - Public Use Data, 2001–2013 - jbk 120616, United States Department of Health and 
Human Services, Centers for Disease Control and Prevention. Released January 2017, based on the 
November 2015 submission. Available at www.cdc.gov/cancer/npcr/public-use. 
Cautionary Notes 
Before using the database, analysts should read and understand the following nuances of the NPCR 
public use data. If you have questions regarding these notes, please contact CDC at npcrdata@cdc.gov.  
Suppression Rules1-2  
When analyzing data at the state or regional levels, counts for national and regional data must be 
suppressed if a single state in a region or division is suppressed. This practice is referred to as 
complementary cell suppression and is necessary to prevent users from subtracting to find suppressed 
counts. Rates, confidence intervals (CIs), and populations can be shown at the national and regional 
levels. This suppression should occur when a single or multiple years of data are being presented.  
The suppression rule is fewer than16 cases for the time period based on rate stability. This suppression 
rule is enforced automatically in this database.  
When the numbers of cases used to compute the incidence rates are small, those rates tend to have poor 
reliability. Therefore, to discourage misinterpretation and misuse of counts, rates, and trends that are 
unstable because of the small number of cases, these statistics are not shown in tables and figures if the 
counts are less than 16 for the time period. A count of less than about 16 in a numerator results in a 
standard error of the rate that is about 25% or more as large as the rate itself. Equivalently, a count of 
less than about 16 results in the width of the 95% confidence interval around the rate being at least as 
large as the rate itself. These relationships were derived under the assumption of a Poisson process and 
with the standard population age distribution close to the observed population age distribution.  
Another important reason for employing a cell suppression threshold value is to protect the confidentiality 
of patients whose data are included in a report by reducing or eliminating the risk of identity disclosure. 
The cell suppression threshold value of 16 is recommended to protect patient confidentiality given the low 
level of geographic and clinical detail provided.  
Note: As a further mechanism to protect data confidentiality, the case listing function in SEER*Stat has 
been disabled for this database.  
Benign Central Nervous System (CNS) Tumors 
Cancer registries began collecting information on nonmalignant brain and other nervous system tumors 
with cases diagnosed in 2004. Collection of these tumors is in accordance with Public Law 107-260, the 
Benign Brain Tumor Cancer Registries Amendment Act, which mandates that NPCR registries collect 
data on all brain and other nervous system tumors with a behavior code of 0 (benign) and those with a 
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behavior code of 1 (borderline), in addition to in situ and malignant tumors. Data for nonmalignant brain 
and other nervous system tumors were available from all registries contributing to this report. 
Primary Site Variables3 
Beginning in diagnosis year 2010, some of the lymphoma and leukemia ICD-O-3 codes were updated 
based on changes from the World Health Organization. The appropriate site recode variables to use to 
include these updates are Site recode ICD-O-3/WHO 2008 for all ages and International Classification of 
Childhood Cancer (ICCC) site recode ICD-O-3/WHO 2008 for the childhood cancer recodes. 
Consider reviewing the variable “Site recode ICD-O-3/WHO 2008” before using the directly coded primary 
site. For more information on the SEER primary site recodes, see http://seer.cancer.gov/siterecode/. 
Histologic Type ICD-O-34-7 
Beginning with 2010 diagnoses, this item also includes histology codes as specified in the 2008 World 
Health Organization (WHO) hematopoietic/lymphoid publication, which are listed on pages 3–5 of the 
NAACCR 2010 Implementation Guidelines and Recommendations, available at  
http://www.naaccr.org/LinkClick.aspx?fileticket=U-3o31G2Lik%3d&tabid=126&mid=466.  
Stage8 
A merged variable, “Merged Summary Stage 2000,” has been created to span two time periods when two 
different staging schemes were used. “SEER Summary Stage 2000” for diagnosis years 2001–2003 and 
the (or “Derived SEER Summary Stage 2000”) for diagnosis years 2004–2013.  
The coding logic for this merged variable is: 
• If a case was diagnosed between 2001 and 2003, stage at diagnosis is recorded using the “SEER 
Summary Stage 2000” variable value.  
• If a case was diagnosed between 2004 and 2013, then the stage at diagnosis is recorded using the 
“Derived SEER Summary Stage 2000” variable value.  
• If the “Derived SEER Summary Stage 2000” variable is blank and a valid value is available for the 
“SEER Summary Stage 2000” variable, that value is used to populate the merged variable. For 
example, if a case was diagnosed in 2013 and “Derived SEER Summary Stage” was blank, but “SEER 
Summary Stage” had a value of “local,” then the merged variable was coded as local stage. 
Otherwise, the merged variable left blank.  
Reporting Delay 
NPCR registries annually submit all eligible years of data to CDC. As a result, cases submitted in 
previous years may be deleted, and new cases diagnosed in previous years may be added. The addition 
of new cases is called a reporting delay. For example, reporting of melanoma cases diagnosed in an 
outpatient facility may be delayed. As a result, the trend in incident melanoma cases might superficially 
appear to have dropped in the most recent year.  
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Checklist for NPCR Public Use Dataset Analyses  
 If you are reporting state-specific ethnicity or race/ethnicity combinations, have you suppressed data 
from the registries that opted out of reporting these data items using the “Stateraceethincl” variable or 
manually in the SEER*Stat Selection tab?1 
 If you are conducting a multiyear analysis and want to restrict it to the states that met reporting 
standards during each of the years, did you use variable USCS0913, USCS0413, or USCS1113 and 
also use the “Year of Diagnosis” variable to restrict to the corresponding year range on the 
SEER*Stat Selection tab? 
• This is important to do during a trend analysis, as the same states need to be included for each 
year being analyzed. 
• The “Year of Diagnosis” variable is used in combination with the predefined USCS variable to 
exclude the nonrelevant years. For example, if USCS0913 is used, then “Year of Diagnosis” 
should also be restricted to diagnosis years 2009–2013 in the SEER*Stat Selection tab. 
• The variable USCS0913 includes states meeting USCS publication criteria for diagnosis years 
2009–2013, USCS0413 for diagnosis years 2004–2013, and USCS0113 for diagnosis years 
2001–2013. If you would like to analyze a range of years other than those predefined variables, 
please contact CDC at npcrdata@cdc.gov and we will create a new variable for you.2 
 If a user-defined primary site variable was created (rather than using the “Site recode ICD-O-3/WHO 
2008” variable): 
• Did you exclude leukemias and lymphomas (9590-9992)? 
• Did you consider excluding Kaposi sarcoma (9140) and mesothelioma (9050–9055)?3 
 If your analysis includes histology, and if appropriate for the cancer site, did you use the “Diagnostic 
Confirmation” variable to specify the analysis be limited to “Microscopically confirmed” cases?4 
 If you are analyzing sex-specific cancers (such as prostate cancer or female breast cancer), did you 
limit the analysis to the appropriate sex to get the correct population denominator?5 
 When reporting rates, have you included the label “per 100,000 persons,” “per 100,000 women,” or 
“per 100,000 men”? 
 Have you included citations for the: 
• Percentage of United States population coverage provided by the database?  
• NPCR Public Use Research Database?6  
 
1 See: “Stateraceethincl,” “Race Recode,” and “Origin recode NHIA” variable descriptions.  
2 See “USCS standard,” “USCS0911,” “USCS0411,” and “USCS0111” variable descriptions. 
3 See Cautionary Notes/Primary Site Variables section. 
4 See “Diagnostic Confirmation” variable descriptions. 
5 See “Sex” variable description. 
6 See Data Citation section. 
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NPCR 2015 Submission 2001–2013 Public Use Database:  
Variable Definition and Frequency 
Please note that the frequencies presented in this document were created with “Malignant Behavior” 
unselected on the SEER*Stat Selection tab. 
• “Malignant Behavior” is a default selection for this database, as this restriction is used by CDC’s NPCR 
and NCI’s SEER programs for generating official cancer statistics.  
This database includes in situ and nonmalignant central nervous system (CNS) cases. These 
nonmalignant cases can be analyzed by unselecting the “Malignant Behavior” check box on the 
SEER*Stat Selection tab.  
• All cases with an unknown age or with sex other than male or female have been excluded from this 
database and are unavailable. The frequency counts presented in this document will not change 
based on whether “Known Age” or “Male or Female Sex” is checked on the SEER*Stat Selection tab.  
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SEER*Stat Item Name: Age recode with <1 year olds  
Source of Standard: NAACCR 
Source Item Name: Derived from “Age at diagnosis” 
Source Item Number: 230  
Description 
This variable indicates age range at diagnosis by grouping patient into one of 19 categories (0, 1–4, 5–9, 
…, 75–79, 80–84, ≥85 years). Derived from the NAACCR variable “Age at diagnosis [230],” which is the 
age (in years) of the patient at diagnosis.  
Considerations for use  
Different primary tumors for the same patient may have different values. Records for persons with 
multiple primary cancers cannot be identified in this database.  
Values Frequency  Percentage 
00 years 13,734 0.1% 
01–04 years 45,353 0.2% 
05–09 years 33,123 0.2% 
10–14 years 39,033 0.2% 
15–19 years 66,224 0.3% 
20–24 years 105,262 0.5% 
25–29 years 165,123 0.8% 
30–34 years  255,934 1.3% 
35–39 years 401,632 2.0% 
40–44 years 709,242 3.6% 
45–49 years 1,144,725 5.7% 
50–54 years 1,682,564 8.4% 
55–59 years 2,143,127 10.7% 
60–64 years 2,471,065 12.4% 
65–69 years  2,672,918 13.4% 
70–74 years 2,531,680 12.7% 
75–79 years 2,301,375 11.5% 
80–84 years 1,751,516 8.8% 
85+ years 1,406,668 7.1% 
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SEER*Stat Item Name: Sex 
Source of Standard: NAACCR 
Source Item Name: Sex  
Source Item Number: 220  
Description 
This variable indicates the sex of the patient.  
Considerations for use  
• To get the correct population denominator, “female” must be selected when analyzing female-specific 
cancers (such as ovarian cancer or female breast cancer) and “male” for male-specific cancers (such 
as prostate cancer). 
• Due to small case counts and the lack of an associated population file, cases for sex other than male 
or female are excluded from this database.  
Values Frequency  Percentage 
Male 9,919,882 49.7% 
Female 10,020,416 50.3% 
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SEER*Stat Name: Year of diagnosis 
Source of Standard: NAACCR  
Source Item Name: Derived from “Date of initial diagnosis (CoC)”  
Source Item Number: 390  
Description 
This variable indicates the year of initial diagnosis by a recognized medical practitioner for the cancer 
being reported, whether clinically or microscopically confirmed. Derived from “Date of initial diagnosis 
(CoC) [390].” 
Considerations for use 
• As an additional confidentiality measure, date of diagnosis is not provided.  
• For more information, please see 
 NAACCR data dictionary http://www.naaccr.org/StandardsandRegistryOperations/VolumeII.aspx 
 FORDS https://www.facs.org/quality-programs/cancer/ncdb/registrymanuals/cocmanuals  
 SEER coding manuals http://seer.cancer.gov/tools/codingmanuals/historical.html  
Values Frequency  Percentage 
2001 1,321,844 6.6% 
2002 1,335,619 6.7% 
2003 1,409,262 7.1% 
2004 1,467,394 7.4% 
2005 1,500,437 7.5% 
2006 1,537,690 7.7% 
2007 1,589,204 8.0% 
2008 1,610,160 8.1% 
2009 1,631,248 8.2% 
2010 1,619,597 8.1% 
2011 1,642,493 8.2% 
2012 1,633,442 8.2% 
2013 1,641,908 8.2% 
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SEER*Stat Item Name: Addr at DX – State 
Source of Standard: NAACCR 
Source Item Name: State at diagnosis (CoC)  
Source Item Number: 80  
Description 
This variable indicates the U.S. state, if funded by NPCR, in which the patient lived at the time the 
reportable tumor was diagnosed.  
Considerations for use  
• If a patient has multiple tumors, the state of residence at the time of diagnosis may differ for each.  
• Multiple records for an individual with more than one primary cancer cannot be linked in this database.  
• For more information, please see 
 NAACCR data dictionary http://www.naaccr.org/StandardsandRegistryOperations/VolumeII.aspx 
 FORDS variable “state at diagnosis” at https://www.facs.org/quality-
programs/cancer/ncdb/registrymanuals/cocmanuals  
Values Frequency  Percentage 
Alaska 35,433 0.2% 
Alabama 331,541 1.7% 
Arkansas 199,787 1.0% 
Arizona 363,444 1.8% 
California 2,180,601 10.9% 
Colorado 284,277 1.4% 
District of Columbia 37,070 0.2% 
Delaware 70,813 0.4% 
Florida 1,482,400 7.4% 
Georgia 574,564 2.9% 
Idaho 95,216 0.5% 
Illinois 890,901 4.5% 
Indiana 439,908 2.2% 
Kansas 195,746 1.0% 
Kentucky 338,471 1.7% 
Louisiana 314,174 1.6% 
Massachusetts 513,492 2.6% 
Maryland 385,102 1.9% 
Maine 116,107 0.6% 
Michigan 752,394 3.8% 
Minnesota 362,349 1.8% 
Missouri 418,794 2.1% 
Mississippi 170,934 0.9% 
Montana 73,679 0.4% 
North Carolina 636,150 3.2% 
North Dakota 47,758 0.2% 
Nebraska 124,535 0.6% 
New Hampshire 105,386 0.5% 
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New Jersey 691,967 3.5% 
Nevada 114,856 0.6% 
New York 1,485,821 7.5% 
Ohio 831,428 4.2% 
Oklahoma 249,863 1.3% 
Oregon 273,249 1.4% 
Pennsylvania 1,062,595 5.3% 
Rhode Island 86,375 0.4% 
South Carolina 321,724 1.6% 
South Dakota 56,963 0.3% 
Tennessee 373,135 1.9% 
Texas 1,316,748 6.6% 
Virginia 425,554 2.1% 
Vermont 50,228 0.3% 
Washington 466,404 2.3% 
Wisconsin 403,943 2.0% 
West Virginia 153,709 0.8% 
Wyoming 34,710 0.2% 
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SEER*Stat Item Name: USCS standard 
Source of Standard: NPCR 
Source Item Name: Derived from NAACCR’s “State at diagnosis (CoC)” and USCS publication standard 
Source Item Number: Derived from NAACCR’s 80 
Description 
This variable indicates the NPCR-funded central cancer registries with cancer incidence data that are of 
high quality and meet the USCS standard for a single year of analysis at the national level for all cancer 
sites combined.  
Considerations for use 
• This variable allows the selection of only those central cancer registries whose data meet the USCS 
standard for an individual diagnosis year.  
• If you are conducting a multiyear analysis and want to restrict the analysis to the states that met 
publication criteria for each of those years (for example, a trend analysis), we recommend using the 
predefined variables, USCS0913 (includes diagnosis years 2009–2013), USCS0413 (includes 
diagnosis years 2004–2013), or USCS0113 (includes diagnosis years 2001–2013). 
• If you would like to analyze a range of years other than those predefined variables, please contact 
CDC at npcrdata@cdc.gov and we will create a new variable for you that can be imported into 
SEER*Stat. 





diagnosis  Frequency  Percentage 
43 2001 1,321,844 6.6% 
42 2002 1,335,619 6.7% 
46 2003 1,409,262 7.1% 
46 2004 1,467,394 7.4% 
46 2005 1,500,437 7.5% 
46 2006 1,537,690 7.7% 
46 2007 1,589,204 8.0% 
46 2008 1,610,160 8.1% 
46 2009 1,631,248 8.2% 
46 2010 1,619,597 8.1% 
45 2011 1,642,493 8.2% 
45 2012 1,633,442 8.2% 
45 2013 1,641,908 8.2% 
a Refer to Table 2 for the list of central cancer registries included in each diagnosis year.  
CCR  central cancer registries   
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SEER*Stat Item Name: USCS0113 
Source of Standard: NPCR 
Source Item Name: Derived from NAACCR’s “State at diagnosis (CoC)” and USCS publication standards  
Source Item Number: Derived from NAACCR’s 80 
Description 
This variable indicates whether NPCR-funded central cancer registries met the USCS publication 
standard for all cancer sites combined each year in 2001–2013. When using this variable, restrict the 
diagnosis years to 2001–2013. This is done in SEER*Stat on the Selection tab using the “Year of 
diagnosis” variable.  
Considerations for use 
• This variable is used for analysis of combined 2001–2013 data in the 2001–2013 database. Data from 
states that did not meet the USCS publication standard in any given year were excluded from the 
database for that year. Please refer to Table 2 for the list of states by year that were included and 
excluded by this variable. 
• If you are conducting a multiyear analysis and want to restrict the analysis to the states that met 
publication criteria for each of those years (for example, a trend analysis), we recommend using the 
predefined variables, USCS0913 (includes diagnosis years 2009–2013), USCS0413 (includes 
diagnosis years 2004–2013), or USCS0113 (includes diagnosis years 2001–2013). 
• If you would like to analyze a range of years other than those predefined variables, please contact 
CDC at npcrdata@cdc.gov and we will create a new variable for you that can be imported into 
SEER*Stat. 
• The USCS publication standard is available at 
https://www.cdc.gov/cancer/npcr/uscs/technical_notes/criteria.htm. 
Values Frequency  Percentage 
Does not meet USCS standard from 2001–2013 1,121,549 5.6% 
Meets USCS standard from 2001–2013 18,818,749 94.4% 
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SEER*Stat Item Name: USCS0413 
Source of Standard: NPCR 
Source Item Name: Derived from NAACCR’s “State at diagnosis (CoC)” and USCS publication standard  
Source Item Number: Derived from NAACCR’s 80 
Description  
This variable indicates whether NPCR-funded central cancer registries met the USCS publication 
standard for all cancer sites combined each year in 2004–2013. When using this variable, restrict the 
diagnosis years to 2004–2013. This is done in SEER*Stat on the Selection tab using the “Year of 
diagnosis” variable.  
Considerations for use 
• This variable is used for analysis of combined 2004–2013 data in the 2001–2013 database. Data from 
states that did not meet the USCS publication standard in any given year were excluded from the 
database for that year. Please refer to Table 2 for the list of states by year that were included and 
excluded by this variable. 
• If you are conducting a multiyear analysis and want to restrict the analysis to the states that met 
publication criteria for each of those years (for example, a trend analysis), we recommend using the 
predefined variables, USCS0913 (includes diagnosis years 2009–2013), USCS0413 (includes 
diagnosis years 2004–2013) or USCS0113 (includes diagnosis years 2001–2013). 
• If you would like to analyze a range of years other than those predefined variables, please contact 
CDC at npcrdata@cdc.gov and we will create a new variable for you that can be imported into 
SEER*Stat. 
• The USCS publication standard is available at 
https://www.cdc.gov/cancer/npcr/uscs/technical_notes/criteria.htm. 
Values Frequency  Percentage 
Does not meet USCS standard from 2004–2013 83,270 0.5% 
Meets USCS standard from 2004–2013 15,790,303 99.5% 
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SEER*Stat Item Name: USCS0913 
Source of Standard: NPCR 
Source Item Name: Derived from NAACCR’s “State at diagnosis (CoC)” and USCS publication standard  
Source Item Number: Derived from NAACCR’s 80 
Description  
This variable indicates whether NPCR-funded central cancer registries met the USCS publication 
standard for all cancer sites combined each year in 2009–2013. When using this variable, restrict the 
diagnosis years to 2009–2013. This is done in SEER*Stat on the Selection tab using the “Year of 
diagnosis” variable.  
Considerations for use 
• This variable is used for analysis of combined 2009–2013 data in the 2001–2013 database. Data from 
states that did not meet the USCS publication standard in any given year were excluded from the 
database for that year. Please refer to Table 2 for the list of states by year that were included and 
excluded by this variable. 
• If you are conducting a multiyear analysis and want to restrict the analysis to the states that met 
publication criteria for each of those years (for example, a trend analysis), we recommend using the 
predefined variables, USCS0913 (includes diagnosis years 2009–2013), USCS0413 (includes 
diagnosis years 2004–2013) or USCS0113 (includes diagnosis years 2001–2013). 
• If you would like to analyze a range of years other than those predefined variables, please contact 
CDC at npcrdata@cdc.gov and we will create a new variable for you that can be imported into 
SEER*Stat. 
• The USCS publication standard is available at 
https://www.cdc.gov/cancer/npcr/uscs/technical_notes/criteria.htm. 
Values Frequency  Percentage 
Does not meet USCS standard from 2009–2013 25,217 0.3% 
Meets USCS standard from 2009–2013 8,143,471 99.7% 
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SEER*Stat Item Name: Region 
Source of Standard: NPCR 
Source Item Name: Derived from NAACCR’s “State at diagnosis (CoC)” and US Census Region  
Source Item Number: Derived from NAACCR’s 80 
Description  
This variable indicates the U.S. Census region in which the patient lived at the time of diagnosis. The 
NAACCR data item “Address at Diagnosis-state” is recoded into one of the four U.S. Census regions: 
Northeast, Midwest, South, and West. 
Considerations for use 
• There is a potential for bias in the incidence rates for Census regions as only data from state registries 
that met USCS publication criteria are included in the database. It is recommended that age-adjusted 
incidence rates for U.S. Census regions be presented only if:  
 At least 80% of the population for the Census region was covered by cancer registries that met 
USCS publication criteria.  
 The 95% confidence intervals around the observed age-adjusted regional incidence rates based on 
data from eligible registries for each of six major cancer sites (prostate, female breast, male 
colorectal, female colorectal, male lung and bronchus, and female lung and bronchus) included the 
estimate of the regional rate calculated using the specified: 
http://www.cdc.gov/cancer/npcr/uscs/data/00_bias_correction.htm.  
• If any state in a region has a case count of less than 16, then the case counts for U.S. Census regions 
cannot be presented.  
• See https://www.census.gov/geo/reference/gtc/gtc_census_divreg.html for a list of states in each 
region.  
Values Frequency  Percentage 
Northeast 4,111,971 20.6% 
Midwest 4,524,719 22.7% 
South 7,381,739 37.0% 
West 3,921,869 19.7% 
  
22 NPCR Public Use Research Data Standards and Data Dictionary 
 
SEER*Stat Item Name: Stateraceethincl 
Source of Standard: NPCR 
Source Item Name: Derived from “Addr at DX - state" and state-level race or ethnicity reporting 
restrictions 
Source Item Number: Derived from NAACCR 80 (Addr at Dx - state) 
Description  
This variable was created specifically for this database. It provides the selection of states that are eligible 
to be included in a state-level analysis of race and ethnicity.  
Considerations for use 
• States have the option to suppress race-specific and Hispanic ethnicity–specific data every submission 
year. While these states can be included in an aggregated analysis, the affected state’s race and 
ethnicity information cannot be reported at the state level.  
• The following states have state-level race or ethnicity data presentation restrictions:  
 Data for American Indians and Alaska Natives cannot be displayed for Delaware, Illinois, Kansas, 
Kentucky, New Jersey, and New York.  
 Data for Asians and Pacific Islanders cannot be displayed for Delaware and Kentucky.  
 Hispanic ethnicity data cannot be displayed for Delaware, Kentucky, Massachusetts, North Dakota, 
and Virginia.  
 Race and ethnicity combinations—white Hispanic, white non-Hispanic, black Hispanic, and black 
non-Hispanic—cannot be displayed for Pennsylvania. 
• For more information, please refer to the “Race Recode for USCS” and “Origin recode NHIA (Hispanic, 
Non-Hisp)” variable descriptions in this document. 
Values Frequency  Percentage 
Exclude state for race/ethnicity state-level analyses 5,723,118 28.7% 
Include state for race/ethnicity state-level analyses 14,217,180 71.3% 
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SEER*Stat Item Name: Race Recode for USCS 
Source of Standard: NAACCR 
Source Item Name: Derived from “Race 1”, “Race 2”, and “race- NAPIIA (derived API)”  
Source Item Number: 160 (Race 1), 161 (Race 2), and 192 (race- NAPIIA (derived API) 
Description  
This variable indicates the derived code for the patient’s race. Race is coded separately from Hispanic 
ethnicity. This variable is created using NAACCR variables “Race1,” “Race2,” the Indian Health Service 
(IHS) Link variable, and “race-NAPIIA (derived API).” Race recode starts as “Race1.” If “Race1” is white 
and “Race 2” is a specified non-white race, then the value from “Race2” is used. After this check, if Race 
is still white and there is a positive IHS link, then “Race/Ethnicity” is set to American Indian/Alaskan Native 
(AI/AN). 
Considerations for use  
• This variable is available only in the 2001–2013 public use database; it is not available in the 2006–
2013 database. 
• States have the option to suppress race-specific and Hispanic-specific data every submission year. 
While these states can be included in an aggregated analysis, their race and ethnicity information 
cannot be reported at the state level.  
• The following states have state-level race data presentation restrictions:  
 Data for American Indians and Alaska Natives cannot be displayed for Delaware, Illinois, Kansas, 
Kentucky, New Jersey, and New York.  
 Data for Asians and Pacific Islanders cannot be displayed for Delaware and Kentucky.  
• Race is defined by specific physical, hereditary, and cultural traditions or origins, not necessarily by 
birthplace, place of residence, or citizenship. “Origin” is defined by the U.S. Census Bureau as the 
heritage, nationality group, lineage, or in some cases, the country of birth of the person or the person’s 
parents or ancestors before their arrival in the United States. 
• IHS provides medical services to American Indians and Alaska Natives (AI/ANs) who are members of 
federally recognized tribes, estimated to be about 65% of the AI/AN population. To improve 
identification of AI/ANs, 31 NPCR registries with Contract Health Service Delivery Area (CHSDA) 
counties in their state annually link with the IHS patient registration database to identify AI/ANs who 
had not been coded as AI/AN (shown in Appendix A). All NPCR registries link every five years. 
Linkages were performed by all NPCR states most recently in 2011 and 2016.  
 When interpreting data results, be aware that AI/AN populations may be undercounted during years 
when linkages did not occur in all NPCR registries. 
 If a project is looking specifically at AI/AN populations, analysts may consider restricting the 
analysis to registries that conduct annual IHS linkages. See Appendix A for the list of these states.  
• In all separate records of tumors for the same patient, the patient should have the same race code.  
• The “Race Recode for USCS” variable contains “other unspecified” and “unknown” categories. These 
groups are coded as “unknown race” for the purpose of analyses as specified in the SEER 
documentation https://seer.cancer.gov/seerstat/variables/seer/race_ethnicity. Population data are not 
available for the “other race” and “unknown race” categories. 
• For more information, please see 
 NAACCR data dictionary http://www.naaccr.org/StandardsandRegistryOperations/VolumeII.aspx 
 FORDS at https://www.facs.org/quality-programs/cancer/ncdb/registrymanuals/cocmanuals  
 SEER coding manuals http://seer.cancer.gov/tools/codingmanuals/historical.html  
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Values Frequency  Percentage 
White 16,999,888 85.3% 
Black 2,080,423 10.4% 
American Indian/Alaska Native 91,078 0.5% 
Asian or Pacific Islander 473,435 2.4% 
Other unspecified (1991+) 67,320 0.3% 
Unknown 228,154 1.1% 
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SEER*Stat Item Name: Origin recode NHIA (Hispanic, Non-Hisp) 
Source of Standard: NAACCR 
Source Item Name: NHIA derived Hisp Origin 
Source Item Number: 191 
Description  
This variable was derived from the NAACCR standard variables: “Spanish/Hispanic Origin [190]”; “Name-
Last [2230]”; “Name-Maiden [2390]”; “Birthplace [250]”; “Race 1 [160]”; “IHS Link [192]”; and “Sex [220].” 
NAACCR Hispanic Identification Algorithm uses the combination of these variables to directly or indirectly 
classify cases as Hispanic for analytic purposes. 
Considerations for use 
• This variable is available only in the 2001–2013 database. 
• States have the option to suppress race-specific and Hispanic-specific data every submission year. 
While these states can be included in an aggregated analysis, the state’s race and ethnicity 
information cannot be reported at the state level.  
• The following states have state-level race or ethnicity data presentation restrictions:  
 Data for Hispanic ethnicity cannot be displayed for Delaware, Kentucky, Massachusetts, North 
Dakota, and Virginia.  
 Data for race and ethnicity combinations—white Hispanic, white non-Hispanic, black Hispanic, and 
black non-Hispanic—cannot be displayed for Pennsylvania. 
• Blank values are allowed for states that chose not to include data for NHIA in this file.  
• Additional information available at 
http://www.naaccr.org/LinkClick.aspx?fileticket=6E20OT41TcA%3d&tabid=118&mid=458. 
Values Frequency  Percentage 
Non-Spanish-Hispanic-Latino 18,587,954 93.2% 
Spanish-Hispanic-Latino 1,292,743 6.5% 
Invalid Value(s) 59,601 0.3% 
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SEER*Stat Item Name: Primary Site – labeled 
Source of Standard: NAACCR 
Source Item Name: Derived from “Primary site” 
Source Item Number: 400  
Description  
This variable indicates the topography code from The International Classification of Diseases for 
Oncology, Third Edition (ICD-O-3) for the primary site of the tumor being reported.  
Considerations for use  
• Beginning in diagnosis year 2010, there were updates to some of the lymphoma and leukemia codes. 
To include these updates, the appropriate primary site variables to use are “Site recode ICD-O-3/WHO 
2008” for all ages, and “ICCC site recode ICD-O-3/WHO 2008” for the childhood cancer recodes.  
• For more information, please see SEER coding manuals 
http://seer.cancer.gov/tools/codingmanuals/historical.html.  
Values Frequency  Percentage 
C00.0-C77.9 (specific site) 19,598,723 98.3% 
C80.9 (Unknown primary site) 341,575 1.7% 
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SEER*Stat Item Name: Histologic Type ICD-O-3 
Source of Standard: NAACCR 
Source Item Name: Histologic Type ICD-O-3 
Source Item Number: 522 
Description  
This variable indicates the morphology code from The International Classification of Diseases for 
Oncology, Third Edition (ICD-O-3) that describes the histologic type (the microscopic composition of cells 
and tissue for a specific primary tumor) of the primary tumor being reported.  
Considerations for use  
• This data item is required for cancer cases diagnosed on or after January 1, 2001.  
•  The histology codes for some tumors may be based on clinical diagnoses, not pathologic 
confirmation. When analyzing a specific histology, we suggest using the “diagnostic confirmation” 
variable in conjunction with this variable. Beginning with 2010 diagnoses, this item also includes 
histology codes as specified in the WHO Classification of Tumours of Haematopoietic and Lymphoid 
Tissues (2008), which are listed on pages 3–5 of the NAACCR 2010 Implementation Guidelines. 
http://www.naaccr.org/StandardsandRegistryOperations/ImplementationGuidelines.aspx.  
• For more Information, please see  
 SEER 2007 Multiple Primary and Histology Coding Rules: 
https://seer.cancer.gov/tools/mphrules/mphrules_instructions.pdf  
 SEER Hematopoietic Project: https://seer.cancer.gov/tools/heme/  
 ICD-O-3 SEER site/Histology validation list: https://seer.cancer.gov/icd-o-3. 
 Surveillance, Epidemiology, and End Results Program. Hematopoietic and Lymphoid Neoplasm 
Database. Bethesda, MD: US Department of Health and Human Services, National Cancer 
Institute; 2016. https://seer.cancer.gov/seertools/hemelymph.  
 Ruhl J, Adamo M, Dickie L. (January 2015). Hematopoietic and Lymphoid Neoplasm Coding 
Manual. National Cancer Institute, Bethesda, MD 20850-9765. 
 International Classification of Diseases for Oncology, Third Edition, First Revision. Geneva: World 
Health Organization, 2013  
Values Frequency  Percentage 
8000–9992  19,940,298 100% 
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SEER*Stat Item Name: Grade 
Source of Standard: NAACCR 
Source Item Name: Grade 
Source Item Number: 440 
Description  
This variable indicates the grade or degree of differentiation of the primary tumor being reported. For 
lymphomas and leukemias, this field also is used to indicate T-, B-, Null-, or NK-cell origin.  
Considerations for use  
• The practice of grading varies greatly among pathologists throughout the world, and many malignant 
tumors are not graded routinely. Since different grading systems may be used, review the site-specific 
modules available at https://training.seer.cancer.gov/modules_site_spec.html and the most current 
FORDS manual (http://www.facs.org/cancer/coc/fordsmanual.html). 
Each module has an abstracting, coding, and staging section, which has a morphology and grading 
subsection. Some modules, but not all, contain notes about the grading system that may have been 
used. Currently, there is no variable to differentiate a specific grading system from another one if more 
than two grading systems are mentioned.  
• Diagnostic practices also influence coding practices. For example, preliminary analysis of tumor grade 
for prostate cancer showed an increase in the proportion of higher grades from 2002 to 2003. 
Additional review showed this increase to be artificial, as the International Society of Urologic 
Pathologists, in conjunction with WHO, had made a series of recommendations for modification of the 
Gleason grading system to reflect contemporary knowledge, alleviate uncertainty, and promote 
uniformity in its application. One recommendation was for pathologists to report all higher tertiary 
grade components of the tumor as part of the Gleason score. Another recommendation was made for 
reporting of any higher grade cancer, no matter how small quantitatively.  
The percentage of cases with a known grade varies by primary cancer site. Rules for coding the tumor 
grade differ for some primary sites. As a result, it may be appropriate to have a tumor grade coded as 
“9 – unknown.” 
Values Frequency  Percentage 
Well differentiated; Grade I 1,682,221 8.4% 
Moderately differentiated; Grade II 5,000,044 25.1% 
Poorly differentiated; Grade III 4,142,206 20.8% 
Undifferentiated; anaplastic; Grade IV 629,794 3.2% 
T-cell 65,704 0.3% 
B-cell; pre-B; B-precursor 888,306 4.5% 
Null cell; non T-non B 2,285 0.0% 
NK cell; natural killer cell (1995+) 2,975 0.0% 
Unknown 7,526,763 37.7% 
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SEER*Stat Item Name: Diagnostic confirmation 
Source of Standard: NAACCR 
Source Item Name: Diagnostic confirmation 
Source Item Number: 490 
Description  
This variable records the best method of diagnostic confirmation of the cancer being reported at any time 
in the patient’s history. The rules for coding differ between solid tumors and hematopoietic and lymphoid 
neoplasms. 
Considerations for use  
• For analyses that include histology, it is recommended that “diagnostic confirmation=microscopically 
confirmed” is selected.  
• Diagnostic confirmation is useful to calculate rates based on microscopically confirmed cancers. Full 
incidence calculations must also include cases that are only confirmed clinically. The percentage of 
cases that are “clinically diagnosed only” is an indication of whether case finding includes sources 
outside of pathology reports.  
• The microscopically confirmed method has the highest priority for diagnostic confirmation. The 
remaining values were assigned when the presence of cancer was confirmed with multiple diagnostic 
methods. 
• “Positive histology AND immunophenotyping AND/OR positive genetic studies” (used only for 
hematopoietic and lymphoid neoplasms M-9590/3-9992/3) was adopted for use beginning with 2010 
diagnoses.  
• For more information, please see: 
 FORDS at https://www.facs.org/quality-programs/cancer/ncdb/registrymanuals/cocmanuals  
 SEER coding manuals https://seer.cancer.gov/tools/codingmanuals/historical.html 
Values Frequency  Percentage 
Microscopically confirmed (total)  18,780,210 94.2% 
Positive histology 18,050,557 90.5% 
Positive exfoliative cytology, no positive histology 633,228 3.2% 
Positive histology AND immunophenotyping AND/OR  
positive genetic studies 
74,185 0.4% 
Positive microscopic confirm, method not specified 22,240 0.1% 
Positive laboratory test/marker study 85,596 0.4% 
Direct visualization without microscopic confirmation 28,787 0.1% 
Radiography without microscopic confirm 671,651 3.4% 
Clinical diagnosis only 115,180 0.6% 
Unknown 258,874 1.3% 
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SEER*Stat Item Name: Site recode ICD-O-3/WHO 2008  
Source of Standard: NAACCR 
Source Item Name: Derived from “Primary site” and “Histologic code ICD-O-3 
Source Item Number: 400 (Primary site) and 522 (Histologic code ICD-O-3) 
 Description  
 This recode variable is defined by the SEER program. The values of the site recode ICD-O-3/WHO 2008 
variable are based on NAACCR variables for ICD-O-3, the primary site and histology code of the primary 
tumor being reported, with updated information for Hematopoietic codes based on WHO Classification of 
Tumours of Haematopoietic and Lymphoid Tissues (2008). The site recode variables define the major 
cancer sites that are commonly used in the reporting of cancer incidence data.  
Considerations for use  
• This is the recommended variable for analyses by primary cancer site.  
• More information is available at https://seer.cancer.gov/siterecode.  
Values Frequency  Percentage 
All Sites (total) 19,940,298  
Oral Cavity and Pharynx 450,695 2.3% 
Lip 27,881 0.1% 
Tongue 129,152 0.6% 
Salivary Gland 47,917 0.2% 
Floor of Mouth 27,579 0.1% 
Gum and Other Mouth 63,293 0.3% 
Nasopharynx 21,455 0.1% 
Tonsil 74,658 0.4% 
Oropharynx 19,434 0.1% 
Hypopharynx 28,754 0.1% 
Other Oral Cavity and Pharynx 10,572 0.1% 
Digestive System 3,377,316 16.9% 
Esophagus 192,536 1.0% 
Stomach 265,156 1.3% 
Small Intestine 82,986 0.4% 
Colon and Rectum 1,892,507 9.5% 
Colon excluding Rectum 1,365,573 6.8% 
Cecum 295,341 1.5% 
Appendix 29,592 0.1% 
Ascending Colon 261,739 1.3% 
Hepatic Flexure 67,129 0.3% 
Transverse Colon 123,003 0.6% 
Splenic Flexure 42,592 0.2% 
Descending Colon 80,807 0.4% 
Sigmoid Colon 374,627 1.9% 
Large Intestine, NOS 90,743 0.5% 
Rectum and Rectosigmoid Junction 526,934 2.6% 
Rectosigmoid Junction 140,086 0.7% 
Rectum 386,848 1.9% 
Anus, Anal Canal and Anorectum 76,433 0.4% 
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Values Frequency  Percentage 
Liver and Intrahepatic Bile Duct 253,957 1.3% 
Liver 227,875 1.1% 
Intrahepatic Bile Duct 26,082 0.1% 
Gallbladder 45,136 0.2% 
Other Biliary 66,157 0.3% 
Pancreas 449,025 2.3% 
Retroperitoneum 14,652 0.1% 
Peritoneum, Omentum and 
Mesentery 23,152 0.1% 
Other Digestive Organs 15,619 0.1% 
Respiratory System 2,730,723 13.7% 
Nose, Nasal Cavity and Middle Ear 27,236 0.1% 
Larynx 164,524 0.8% 
Lung and Bronchus 2,530,541 12.7% 
Pleura 1,181 0.0% 
Trachea, Mediastinum and Other 
Respiratory Organs 7,241 0.0% 
Bones and Joints 35,136 0.2% 
Soft Tissue including Heart 121,724 0.6% 
Skin excluding Basal and Squamous 1,269,626 6.4% 
Melanoma of the Skin 1,208,036 6.1% 
Other Non-Epithelial Skin 61,590 0.3% 
Breast (female and male combined) 3,236,959 16.2% 
Female Genital System 1,062,781 5.3% 
Cervix Uteri 155,617 0.8% 
Corpus and Uterus, NOS 531,883 2.7% 
Corpus Uteri 516,648 2.6% 
Uterus, NOS 15,235 0.1% 
Ovary 261,350 1.3% 
Vagina 17,574 0.1% 
Vulva 77,252 0.4% 
Other Female Genital Organs 19,105 0.1% 
Male Genital System 2,696,874 13.5% 
Prostate 2,571,765 12.9% 
Testis 98,516 0.5% 
Penis 22,108 0.1% 
Other Male Genital Organs 4,485 0.0% 
Urinary System 1,476,190 7.4% 
Urinary Bladder 821,670 4.1% 
Kidney and Renal Pelvis 608,089 3.0% 
Ureter 32,183 0.2% 
Other Urinary Organs 14,248 0.1% 
Eye and Orbit 36,556 0.2% 
Brain and Other Nervous System 584,055 2.9% 
Brain 270,350 1.4% 
Cranial Nerves Other Nervous 
System 313,705 1.6% 
Endocrine System 575,302 2.9% 
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Values Frequency  Percentage 
Thyroid 439,865 2.2% 
Other Endocrine including Thymus 135,437 0.7% 
Lymphoma 849,274 4.3% 
Hodgkin Lymphoma 103,730 0.5% 
Hodgkin – Nodal 100,539 0.5% 
Hodgkin – Extranodal 3,191 0.0% 
Non-Hodgkin Lymphoma 745,544 3.7% 
NHL – Nodal 510,020 2.6% 
NHL – Extranodal 235,524 1.2% 
Myeloma 234,170 1.2% 
Leukemia 497,533 2.5% 
Lymphocytic Leukemia 247,594 1.2% 
Acute Lymphocytic Leukemia 56,710 0.3% 
Chronic Lymphocytic Leukemia 174,384 0.9% 
Other Lymphocytic Leukemia 16,500 0.1% 
Myeloid and Monocytic Leukemia 224,212 1.1% 
Acute Myeloid Leukemia 145,332 0.7% 
Acute Monocytic Leukemia 9,439 0.0% 
Chronic Myeloid Leukemia 62,519 0.3% 
Other Myeloid/Monocytic Leukemia 6,922 0.0% 
Other Leukemia 25,727 0.1% 
Other Acute Leukemia 9,960 0.0% 
Aleukemic, Subleukemic and NOS 15,767 0.1% 
Mesothelioma 38,890 0.2% 
Kaposi Sarcoma 16,150 0.1% 
Miscellaneous 650,344 3.3% 
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SEER*Stat Item Name: ICCC site recode ICD-O-3/WHO 2008  
Source of Standard: SEER 
Source Item Name:  Derived from NAACCR “Primary site,” “Histologic code ICD-O-3,” and “Behavior code 
ICD-O-3”  
Source Item Number:  NAACCR 400 (Primary site), 522 (Histologic code ICD-O-3), and 523 (Behavior 
code ICD-O-3)  
Description  
This variable indicates the classification of childhood cancer, which is based on tumor morphology and 
primary site, and emphasizes morphology rather than primary site, as is done for adults. 
Considerations for use  
• This recode is defined by the SEER program, which was based on definitions presented in Steliarova-
Foucher E, Stiller C, Lacour B, Kaatsch P. International Classification of Childhood Cancer, Third 
Edition.  
• Additional information is available at https://seer.cancer.gov/iccc/iccc3.html. 
Note: This frequency table is restricted to individuals 19 years old or younger 
Values Frequency  Percentage 
I Leukemias, myeloproliferative & myelodysplastic diseases 46,936 23.8% 
 I(a) Lymphoid leukemias 33,560 17.0% 
 I(b) Acute myeloid leukemias 8,127 4.1% 
 I(c) Chronic myeloproliferative diseases 2,371 1.2% 
 I(d) Myelodysplastic syndrome and other myeloproliferative 1,556 0.8% 
 I(e) Unspecified and other specified leukemias 1,322 0.7% 
II Lymphomas and reticuloendothelial neoplasms 26,434 13.4% 
 II(a) Hodgkin lymphomas 12,667 6.4% 
 II(b) Non-Hodgkin lymphomas (except Burkitt lymphoma) 8,859 4.5% 
 II(c) Burkitt lymphoma 2,445 1.2% 
 II(d) Miscellaneous lymphoreticular neoplasms 2,132 1.1% 
 II(e) Unspecified lymphomas 331 0.2% 
III CNS and misc intracranial and intraspinal neoplasms 43,714 22.1% 
 III(a) Ependymomas and choroid plexus tumor 3,638 1.8% 
 III(b) Astrocytomas 16,616 8.4% 
 III(c) Intracranial and intraspinal embryonal tumors 6,255 3.2% 
 III(d) Other gliomas 5,531 2.8% 
 III(e) Other specified intracranial/intraspinal neoplasms 10,189 5.2% 
 III(f) Unspecified intracranial and intraspinal neoplasms 1,485 0.8% 
IV Neuroblastoma and other peripheral nervous cell tumors 8,680 4.4% 
 IV(a) Neuroblastoma and ganglioneuroblastoma 8,448 4.3% 
 IV(b) Other peripheral nervous cell tumors 232 0.1% 
V Retinoblastoma 3,210 1.6% 
VI Renal tumors 7,009 3.5% 
 VI(a) Nephroblastoma and other nonepithelial renal tumors 6,322 3.2% 
 VI(b) Renal carcinomas 660 0.3% 
 VI(c) Unspecified malignant renal tumors 27 0.0% 
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VII Hepatic tumors 2,263 1.1% 
 VII(a) Hepatoblastoma 1,648 0.8% 
 VII(b) Hepatic carcinomas 594 0.3% 
 VII(c) Unspecified malignant hepatic tumors 21 0.0% 
VIII Malignant bone tumors 9,078 4.6% 
 VIII(a) Osteosarcomas 5,157 2.6% 
 VIII(b) Chondrosarcomas 342 0.2% 
 VII(c) Ewing tumor and related sarcomas of bone 2,976 1.5% 
 VIII(d) Other specified malignant bone tumors 421 0.2% 
 VIII(e) Unspecified malignant bone tumors 182 0.1% 
IX Soft tissue and other extraosseous sarcomas 12,270 6.2% 
 IX(a) Rhabdomyosarcomas 4,850 2.5% 
 IX(b) Fibrosarcomas, peripheral nerve & other fibrous 1,321 0.7% 
 IX(c) Kaposi sarcoma 50 0.0% 
 IX(d) Other specified soft tissue sarcomas 4,746 2.4% 
 IX(e) Unspecified soft tissue sarcomas 1,303 0.7% 
X Germ cell & trophoblastic tumors & neoplasms of gonads 11,690 5.9% 
 X(a) Intracranial & intraspinal germ cell tumors 2,043 1.0% 
 X(b) Extracranial & extragonadal germ cell tumors 1,457 0.7% 
 X(c) Malignant gonadal germ cell tumors 7,418 3.8% 
 X(d) Gonadal carcinomas 435 0.2% 
 X(e) Other and unspecified malignant gonadal tumors 337 0.2% 
XI Other malignant epithelial neoplasms and melanomas 18,503 9.4% 
 XI(a) Adrenocortical carcinomas 222 0.1% 
 XI(b) Thyroid carcinomas 7,754 3.9% 
 XI(c) Nasopharyngeal carcinomas 612 0.3% 
 XI(d) Malignant melanomas 5,367 2.7% 
 XI(e) Skin carcinomas 92 0.0% 
 XI(f) Other and unspecified carcinomas 4,456 2.3% 
XII Other and unspecified malignant neoplasms 798 0.4% 
 XII(a) Other specified malignant tumors 410 0.2% 
 XII(b) Other unspecified malignant tumors 388 0.2% 
Not classified by ICCC or in situ 6,882 3.5% 
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SEER*Stat Item Name: ICCC site rec extended ICD-O-3/WHO 2008  
Source of Standard: SEER 
Source Item Name:  Derived from NAACCR “Primary site”, “Histologic code ICD-O-3”, and “Behavior code 
ICD-O-3” 
Source Item Number:  NAACCR 400 (Primary site), 522 (Histologic code ICD-O-3), and 523 (Behavior 
code ICD-O-3) 
Description  
This variable indicates the classification of childhood cancer, which is based on tumor morphology and 
primary site, and emphasizes morphology rather than primary site, as is done for adults. This variable 
contains extended classification codes of childhood cancer, based on definitions presented in 
International Classification of Childhood Cancer, Third Edition (ICCC, 3rd Edition) and WHO Classification 
of Tumours of Haematopoietic and Lymphoid Tissues (2008). 
Considerations for use  
• For comparison of “ICCC site recode ICD-O-3/WHO 2008” and this variable, please visit 
https://seer.cancer.gov/iccc/iccc-who2008.html. 
• Additional information is available at http://seer.cancer.gov/iccc/iccc3_ext.html. 
Values Frequency  Percentage 
I Leukemias, myeloproliferative & myelodysplastic diseases 46,936 23.8% 
 I(a) Lymphoid leukemias 33,560 17.0% 
 I(a.1) Precursor cell leukemias 32,567 16.5% 
 I(a.2) Mature B-cell leukemias 737 0.4% 
 I(a.3) Mature T-cell and NK cell leukemias 104 0.1% 
 I(a.4) Lymphoid leukemia, NOS 152 0.1% 
 I(b) Acute myeloid leukemias 8,127 4.1% 
 I(c) Chronic myeloproliferative diseases 2,371 1.2% 
 I(d) Myelodysplastic syndrome and other myeloproliferative 1,556 0.8% 
 I(e) Unspecified and other specified leukemias 1,322 0.7% 
II Lymphomas and reticuloendothelial neoplasms 26,434 13.4% 
 II(a) Hodgkin lymphomas 12,667 6.4% 
 II(b) Non-Hodgkin lymphomas (except Burkitt lymphoma) 8,859 4.5% 
 II(b.1) Precursor cell lymphomas 2,519 1.3% 
 II(b.2) Mature B-cell lymphomas except Burkitt lymphoma 3,646 1.8% 
 II(b.3) Mature T-cell and NK-cell lymphomas 2,214 1.1% 
 II(b.4) Non-Hodgkin lymphomas, NOS 480 0.2% 
 II(c) Burkitt lymphoma 2,445 1.2% 
 II(d) Miscellaneous lymphoreticular neoplasms 2,132 1.1% 
 II(e) Unspecified lymphomas 331 0.2% 
III CNS and misc intracranial and intraspinal neoplasms 43,714 22.1% 
 III(a) Ependymomas and choroid plexus tumor 3,638 1.8% 
 III(a.1) Ependymomas 2,821 1.4% 
 III(a.2) Choroid plexus tumor 817 0.4% 
 III(b) Astrocytomas 16,616 8.4% 
 III(c) Intracranial and intraspinal embryonal tumors 6,255 3.2% 
 III(c.1) Medulloblastomas 3,976 2.0% 
 III(c.2) PNET 1,439 0.7% 
 III(c.3) Medulloepithelioma 54 0.0% 
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 III(c.4) Atypical teratoid/rhabdoid tumor 786 0.4% 
 III(d) Other gliomas 5,531 2.8% 
 III(d.1) Oligodendrogliomas 713 0.4% 
 III(d.2) Mixed and unspecified gliomas 4,698 2.4% 
 III(d.3) Neuroepithelial glial tumors of uncertain orig 120 0.1% 
 III(e) Other specified intracranial/intraspinal neoplasms 10,189 5.2% 
 III(e.1) Pituitary adenomas and carcinomas 3,998 2.0% 
 III(e.2) Tumors of sellar region (craniopharyngiomas) 1,578 0.8% 
 III(e.3) Pineal parenchymal tumors 441 0.2% 
 III(e.4) Neuronal and mixed neuronal-glial tumors 3,035 1.5% 
 III(e.5) Meningiomas 1,137 0.6% 
 III(f) Unspecified intracranial and intraspinal neoplasms 1,485 0.8% 
IV Neuroblastoma and other peripheral nervous cell tumors 8,680 4.4% 
 IV(a) Neuroblastoma and ganglioneuroblastoma 8,448 4.3% 
 IV(b) Other peripheral nervous cell tumors 232 0.1% 
V Retinoblastoma 3,210 1.6% 
VI Renal tumors ^1 ^1 
 VI(a) Nephroblastoma and other nonepithelial renal tumors ^1 ^1 
 VI(a.1) Nephroblastoma 5,945 3.0% 
 VI(a.2) Rhabdoid renal tumor 160 0.1% 
 VI(a.3) Kidney sarcomas 208 0.1% 
 VI(a.4) pPNET of kidney ^2 ^2 
 VI(b) Renal carcinomas 660 0.3% 
 VI(c) Unspecified malignant renal tumors 27 0.0% 
VII Hepatic tumors 2,263 1.1% 
 VII(a) Hepatoblastoma 1,648 0.8% 
 VII(b) Hepatic carcinomas 594 0.3% 
 VII(c) Unspecified malignant hepatic tumors 21 0.0% 
VIII Malignant bone tumors 9,078 4.6% 
 VIII(a) Osteosarcomas 5,157 2.6% 
 VIII(b) Chondrosarcomas 342 0.2% 
 VIII(c) Ewing tumor and related sarcomas of bone 2,976 1.5% 
 VIII(c.1) Ewing tumor and Askin tumor of bone 2,863 1.4% 
 VIII(c.2) pPNET of bone 113 0.1% 
 VIII(d) Other specified malignant bone tumors 421 0.2% 
 VIII(d.1) Malignant fibrous neoplasms of bone 42 0.0% 
 VIII(d.2) Malignant chordomas 193 0.1% 
 VIII(d.3) Odontogenic malignant tumors 58 0.0% 
 VIII(d.4) Miscellaneous malignant bone tumors 128 0.1% 
 VIII(e) Unspecified malignant bone tumors 182 0.1% 
IX Soft tissue and other extraosseous sarcomas 12,270 6.2% 
 IX(a) Rhabdomyosarcomas 4,850 2.5% 
 IX(b) Fibrosarcomas, peripheral nerve & other fibrous 1,321 0.7% 
 IX(b.1) Fibroblastic and myofibroblastic tumors 695 0.4% 
 IX(b.2) Nerve sheath tumors 608 0.3% 
 IX(b.3) Other fibromatous neoplasms 18 0.0% 
 IX(c) Kaposi sarcoma 50 0.0% 
 IX(d) Other specified soft tissue sarcomas 4,746 2.4% 
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 IX(d.1) Ewing tumor and Askin tumor of soft tissue 604 0.3% 
 IX(d.2) pPNET of soft tissue 294 0.1% 
 IX(d.3) Extrarenal rhabdoid tumor 239 0.1% 
 IX(d.4) Liposarcomas 259 0.1% 
 IX(d.5) Fibrohistiocytic tumors 1,195 0.6% 
 IX(d.6) Leiomyosarcomas 196 0.1% 
 IX(d.7) Synovial sarcomas 1,085 0.5% 
 IX(d.8) Blood vessel tumors 183 0.1% 
 IX(d.9) Osseous & chondromatous neoplasms of soft tissue 104 0.1% 
 IX(d.10) Alveolar soft parts sarcoma 154 0.1% 
 IX(d.11) Miscellaneous soft tissue sarcomas 433 0.2% 
 IX(e) Unspecified soft tissue sarcomas 1,303 0.7% 
X Germ cell & trophoblastic tumors & neoplasms of gonads ^1 ^1 
 X(a) Intracranial & intraspinal germ cell tumors ^1 ^1 
 X(a.1) Intracranial & intraspinal germinomas 1,287 0.7% 
 X(a.2) Intracranial & intraspinal teratomas 506 0.3% 
 X(a.3) Intracranial & intraspinal embryonal carcinomas 22 0.0% 
 X(a.4) Intracranial & intraspinal yolk sac tumor 33 0.0% 
 X(a.5) Intracranial & intraspinal choriocarcinoma ^2 ^2 
 X(a.6) Intracranial & intraspinal tumors of mixed forms 181 0.1% 
 X(b) Extracranial & extragonadal germ cell tumors 1,457 0.7% 
 X(b.1) Germinomas: extracranial/extragonadal 148 0.1% 
 X(b.2) Malignant teratomas: extracranial/extragonadal 565 0.3% 
 X(b.3) Embryonal carcinomas: extracranial/extragonadal 17 0.0% 
 X(b.4) Yolk sac tumor: extracranial/extragonadal 331 0.2% 
 X(b.5) Choriocarcinomas: extracranial/extragonadal 180 0.1% 
 X(b.6) Other mixed germ cell: extracranial/extragonadal 216 0.1% 
 X(c) Malignant gonadal germ cell tumors 7,418 3.8% 
 X(c.1) Malignant gonadal germinomas 1,546 0.8% 
 X(c.2) Malignant gonadal teratomas 1,306 0.7% 
 X(c.3) Gonadal embryonal carcinomas 763 0.4% 
 X(c.4) Gonadal yolk sac tumor 733 0.4% 
 X(c.5) Gonadal choriocarcinoma 73 0.0% 
 X(c.6) Malignant gonadal tumors of mixed forms 2,997 1.5% 
 X(d) Gonadal carcinomas 435 0.2% 
 X(e) Other and unspecified malignant gonadal tumors 337 0.2% 
XI Other malignant epithelial neoplasms and melanomas 18,503 9.4% 
 XI(a) Adrenocortical carcinomas 222 0.1% 
 XI(b) Thyroid carcinomas 7,754 3.9% 
 XI(c) Nasopharyngeal carcinomas 612 0.3% 
 XI(d) Malignant melanomas 5,367 2.7% 
 XI(e) Skin carcinomas 92 0.0% 
 XI(f) Other and unspecified carcinomas 4,456 2.3% 
 XI(f.1) Carcinomas of salivary glands 905 0.5% 
 XI(f.2) Carcinomas of colon and rectum 599 0.3% 
 XI(f.3) Carcinomas of appendix 502 0.3% 
 XI(f.4) Carcinomas of lung 484 0.2% 
 XI(f.5) Carcinomas of thymus 67 0.0% 
 XI(f.6) Carcinomas of breast 213 0.1% 
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 XI(f.7) Carcinomas of cervix uteri 162 0.1% 
 XI(f.8) Carcinomas of bladder 306 0.2% 
 XI(f.9) Carcinomas of eye 31 0.0% 
 XI(f.10) Carcinomas of other specified sites 1,015 0.5% 
 XI(f.11) Carcinomas of unspecified site 172 0.1% 
XII Other and unspecified malignant neoplasms ^1 ^1 
 XII(a) Other specified malignant tumors ^1 ^1 
 XII(a.1) Gastrointestinal stromal tumor 98 0.0% 
 XII(a.2) Pancreatoblastoma 34 0.0% 
 XII(a.3) Pulmonary blastoma and pleuropulmonary blastoma 187 0.1% 
 XII(a.4) Other complex mixed and stromal neoplasms 49 0.0% 
 XII(a.5) Mesothelioma 41 0.0% 
 XII(a.6) Other specified malignant tumors ^2 ^2 
 XII(b) Other unspecified malignant tumors 388 0.2% 
Not classified by ICCC or in situ 6,882 3.5% 
1 Values are not reported due to the need for complementary cell suppression. 
2 Counts of fewer than 16 cases and the corresponding percentages are suppressed. 
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SEER*Stat Item Name: AYA site recode ICD-O-3/WHO 2008 
Source of Standard: SEER 
Source Item Name: Derived from NAACCR “Primary site”, “Histologic code ICD-O-3”, and “Behavior code 
ICD-O-3” 
Source Item Number: NAACCR 400 (Primary site), 522 (Histologic code ICD-O-3), and 523 (Behavior 
code ICD-O-3)  
Description  
This variable was based on ICD-O-3, updated for Hematopoietic codes based on WHO Classification of 
Tumours of Haematopoietic and Lymphoid Tissues (2008). It was developed to better define the major 
cancer sites that affect adolescents or young adults between 15 and 29 years of age.  
Considerations for use  
This recode variable is defined by the SEER program. It was based on definitions proposed by RD Barr 
and colleagues in Barr RD, Holowaty EJ, Birch JM. Classification Scheme for tumors diagnosed in 
adolescents and young adults. Cancer 2006;106(7):1425–30. For more information, please visit 
https://seer.cancer.gov/ayarecode. 
Note: This frequency table is restricted to individuals 19 years old or younger 
Values Frequency  Percentage 
1 Leukemias 20,980 6.2% 
 1.1 Acute lymphoid leukemia 8,208 2.4% 
 1.2 Acute myeloid leukemia 7,961 2.4% 
 1.3 Chronic myeloid leukemia 3,213 1.0% 
 1.4 Other and unspecified leukemia 1,598 0.5% 
2 Lymphomas 49,958 14.8% 
 2.1 Non-Hodgkin lymphoma 19,251 5.7% 
 2.2 Hodgkin lymphoma 30,707 9.1% 
3 CNS and Oth Intracranial and Intraspinal Neo (all behav) 29,956 8.9% 
 3.1. Astrocytoma 10,194 3.0% 
 3.1.1 Specified low-grade astrocytic tumors 4,092 1.2% 
 3.1.2 Glioblastoma and anaplastic astrocytoma 3,759 1.1% 
 3.1.3 Astrocytoma, NOS 2,343 0.7% 
 3.2 Other glioma 5,439 1.6% 
 3.3 Ependymoma 2,024 0.6% 
 3.4. Medulloblastoma and other PNET 1,811 0.5% 
 3.4.1 Medulloblastoma 999 0.3% 
 3.4.2 Supratentorial PNET 812 0.2% 
 3.5 Other specified intracranial and intraspinal neoplasms 8,825 2.6% 
 3.6 Unspecified intracranial and intraspinal neoplasms  1,663 0.5% 
 3.6.1 Unspec malignant intracranial and intraspinal neo 309 0.1% 
 3.6.2 Unspec ben/border intracran. and intraspin neo 1,354 0.4% 
4 Osseous & Chondromatous Neoplasms 8,853 2.6% 
 4.1 Osteosarcoma 3,903 1.2% 
 4.2 Chondrosarcoma 1,172 0.3% 
 4.3 Ewing tumor 2,975 0.9% 
 4.4 Other specified and unspecified bone tumors 803 0.2% 
5 Soft Tissue Sarcomas 14,569 4.3% 
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 5.1 Fibromatous neoplasms 3,666 1.1% 
 5.2 Rhabdomyosarcoma 1,675 0.5% 
 5.3 Other soft tissue sarcoma 9,228 2.7% 
 5.3.1 Specified soft tissue sarcoma 7,157 2.1% 
 5.3.1.1 Specified (excluding Kaposi sarcoma) 5,749 1.7% 
 5.3.1.2 Kaposi sarcoma 1,408 0.4% 
 5.3.2 Unspecified soft tissue sarcoma 2,071 0.6% 
6 Germ Cell and Trophoblastic Neoplasms 40,007 11.9% 
 6.1 Germ cell and trophoblastic neoplasms of gonads 36,483 10.8% 
 6.2 Germ cell and trophoblastic neo of nongonadal sites 3,524 1.0% 
 6.2.1 Intracranial (all behaviors) 1,311 0.4% 
 6.2.2 Other nongonadal 2,213 0.7% 
7 Melanoma and Skin Carcinomas 32,055 9.5% 
 7.1 Melanoma 31,789 9.4% 
 7.2 Skin carcinomas 266 0.1% 
8 Carcinomas 97,098 28.8% 
 8.1 Thyroid carcinoma 41,367 12.3% 
 8.2 Other carcinoma of head and neck 5,663 1.7% 
 8.2.1 Nasopharyngeal carcinoma 1,057 0.3% 
 8.2.2 Other sites in lip, oral cavity and pharynx 4,060 1.2% 
 8.2.3 Nasal cav,mid ear,sinus,larynx,ill-def head/neck 546 0.2% 
 8.3 Carcinoma of trachea,bronchus, and lung 2,434 0.7% 
 8.4 Carcinoma of breast 12,313 3.7% 
 8.5 Carcinoma of genitourinary tract 19,933 5.9% 
 8.5.1 Carcinoma of kidney 4,000 1.2% 
 8.5.2 Carcinoma of bladder 1,749 0.5% 
 8.5.3 Carcinoma of gonads 3,068 0.9% 
 8.5.4 Carcinoma of cervix and uterus 10,570 3.1% 
 8.5.5 Carc of oth and ill-de41enitourinaryiourinary tract 546 0.2% 
 8.6 Carcinoma of gastrointestinal tract 13,529 4.0% 
 8.6.1 Carcinoma of colon and rectum 8,888 2.6% 
 8.6.2 Carcinoma of stomach 1,392 0.4% 
 8.6.3 Carcinoma of liver and intrahepatic bile ducts 1,367 0.4% 
 8.6.4 Carcinoma of pancreas 924 0.3% 
 8.6.5 Carc oth and ill-def sites, gastrointestinal tract 958 0.3% 
 8.7 Carcinoma of other and ill-def sites 1,859 0.6% 
 8.7.1 Adrenocortical carcinoma 287 0.1% 
 8.7.2 Carcinoma of other and ill-defined sites, NOS 1,572 0.5% 
9 Miscellaneous specified neoplasms, NOS 7,545 2.2% 
 9.1 Other pediatric and embryonal tumors, NOS 787 0.2% 
 9.1.1 Wilms tumor 151 0.0% 
 9.1.2 Neuroblastoma 235 0.1% 
 9.1.3 Other pediatric and embryonal tumors, NOS 401 0.1% 
 9.2 Other specified and embryonal tumors, NOS 6,758 2.0% 
 9.2.1 Paraganglioma and glomus tumors 281 0.1% 
 9.2.2 Other specified gonadal tumors 571 0.2% 
 9.2.3 Myeloma, mast cell, misc lymphoreticular neo, NOS 1,140 0.3% 
 9.2.4 Other specified neoplasms, NOS 4,766 1.4% 
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10 Unspecified Malignant Neoplasms 1,853 0.6% 
Unclassified and Non-Malignant 33,735 10.0% 
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SEER*Stat Item Name: Lymphoma subtype recode/WHO 2008 
Source of Standard: SEER 
Source Item Name:  Derived from NAACCR “Primary site”, “Histologic code ICD-O-3”, and “Behavior code  
ICD-O-3” 
Source Item Number:  NAACCR 400 (Primary site), 522 (Histologic code ICD-O-3), and 523 (Behavior 
code ICD-O-3)  
Description  
This variable was based on ICD-O-3, updated for Hematopoietic codes based on WHO Classification of 
Tumours of Haematopoietic and Lymphoid Tissues (2008). It was designed to facilitate epidemiologic 
studies of lymphoma subtypes. 
Considerations for use  
• This recode variable is defined by the SEER program. It was adapted from a proposed nested 
classification of lymphoid neoplasms in:  
Morton LM, et al. Proposed classification of lymphoid neoplasms for epidemiologic research from the 
Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). 
Blood 2007;110:695–708.  
• More information is available at https://seer.cancer.gov/lymphomarecode. 
Values Frequency  Percentage 
Lymphoid Neoplasm 1,349,615 6.8% 
 1 Hodgkin Lymphoma 103,730 0.5% 
 1(a) Classical Hodgkin lymphoma 98,682 0.5% 
 1(a)1 Lymphocyte-rich/mixed cell/lymphocyte depleted 17,219 0.1% 
 1(a)1.1 Lymphocyte-rich 3,663 0.0% 
 1(a)1.2 Mixed cellularity 12,219 0.1% 
 1(a)1.3 Lymphocyte-depleted 1,337 0.0% 
 1(a)2 Nodular sclerosis 57,398 0.3% 
 1(a)3 Classical Hodgkin lymphoma, NOS 24,065 0.1% 
 1(b) Nodular lymphocyte predominant Hodgkin lymphoma 5,048 0.0% 
 2 Non-Hodgkin lymphoma 1,204,317 6.0% 
 2(a) Non-Hodgkin lymphoma, B-cell 1,106,902 5.6% 
 2(a)1 Precursor Non-Hodgkin lymphoma, B-cell 43,269 0.2% 
 2(a)2 Mature Non-Hodgkin lymphoma, B-cell 1,007,328 5.1% 
 2(a)2.1 Chronic/Sm/Prolymphocytic/Mantle B-cell NHL 249,869 1.3% 
 2(a)2.1.1 Chronic/Small lymphocytic leuk/lymph 218,555 1.1% 
 2(a)2.1.2 Prolymphocytic leukemia, B-cell 1,025 0.0% 
 2(a)2.1.3 Mantle-cell lymphoma 30,289 0.2% 
 2(a)2.2 Lymphoplasmacytic lymphoma/Waldenstrom 22,594 0.1% 
 2(a)2.2.1 Lymphoplasmacytic lymphoma 9,702 0.0% 
 2(a)2.2.2 Waldenstrom macroglubulinemia 12,892 0.1% 
 2(a)2.3 Diffuse large B-cell lymphoma (DLBCL) 260,353 1.3% 
 2(a)2.3.1 DLBCL, NOS 257,919 1.3% 
 2(a)2.3.2 Intravascular large B-cell lymphoma 450 0.0% 
 2(a)2.3.3 Primary effusion lymphoma 308 0.0% 
 2(a)2.3.4 Mediastinal large B-cell lymphoma 1,676 0.0% 
 2(a)2.4 Burkitt lymphoma/leukemia 15,090 0.1% 
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 2(a)2.5 Marginal-zone lymphoma (MZL) 68,500 0.3% 
 2(a)2.5.1 Splenic MZL 6,013 0.0% 
 2(a)2.5.2 Extranodal MZL, MALT type 41,334 0.2% 
 2(a)2.5.3 Nodal MZL 21,153 0.1% 
 2(a)2.6 Follicular lymphoma 144,318 0.7% 
 2(a)2.7 Hairy-cell leukemia 11,111 0.1% 
 2(a)2.8 Plasma cell neoplasms 235,298 1.2% 
 2(a)2.8.1 Plasmacytoma 15,931 0.1% 
 2(a)2.8.2 Multiple myeloma/plasma-cell leuk 219,367 1.1% 
 2(a)2.9 Heavy chain disease 195 0.0% 
 2(a)3 Non-Hodgkin lymphoma, B-cell, NOS 56,305 0.3% 
 2(b) Non-Hodgkin lymphoma, T-cell 77,218 0.4% 
 2(b)1 Precursor Non-Hodgkin lymphoma, T-cell 4,497 0.0% 
 2(b)2 Mature Non-Hodgkin lymphoma, T-cell 72,217 0.4% 
 2(b)2.1 Mycosis fungoides/Sezary syndrome 15,386 0.1% 
 2(b)2.1.1 Mycosis fungoides 14,820 0.1% 
 2(b)2.1.2 Sezary syndrome 566 0.0% 
 2(b)2.2 Peripheral T-cell lymphoma 43,244 0.2% 
 2(b)2.2.1 Peripheral T-cell lymphoma, NOS 15,066 0.1% 
 2(b)2.2.2 Angioimmunoblastic T-cell lymphoma 4,585 0.0% 
 2(b)2.2.3 Subcutan panniculitis-like T-cell lymph 371 0.0% 
 2(b)2.2.4 Anaplastic lar cell lymph, T-/Null-cell 10,114 0.1% 
 2(b)2.2.5 Hepatosplenic T-cell lymphoma 325 0.0% 
 2(b)2.2.6 Enteropathy-type T-cell lymphoma 501 0.0% 
 2(b)2.2.7 Cutaneous T-cell lymphoma, NOS 8,847 0.0% 
 2(b)2.2.8 Prim cutaneous anaplastic lar cell lymph 3,435 0.0% 
 2(b)2.3 Adult T-cell leukemia/lymphoma 7,231 0.0% 
 2(b)2.4 NK/T-cell lymph, nasal-type/aggres NK leuk 2,302 0.0% 
 2(b)2.5 T-cell large granular lymphocytic leukemia 2,745 0.0% 
 2(b)2.6 Prolymphocytic leukemia, T-cell 1,309 0.0% 
 2(b)3 Non-Hodgkin lymphoma, NOS, T-cell 504 0.0% 
 2(c) Non-Hodgkin lymphoma, unknown lineage 20,197 0.1% 
 2(c)1 Precursor lymphoblastic leuk/lymph, unk lineage 7,720 0.0% 
 2(c)2 Prolymphocytic leukemia, unknown lineage 569 0.0% 
 2(c)3 Non-Hodgkin lymphoma, NOS, unknown lineage 11,908 0.1% 
 3 Composite Hodgkin lymphoma and NHL 1,339 0.0% 
 4 Lymphoid neoplasm, NOS 40,229 0.2% 
Unclassified 18,590,683 93.2% 
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SEER*Stat Item Name: Behavior Recode for analysis derived/WHO2008 
Source of Standard: NAACCR 
Source Item Name: Behavior code ICD-O-3 
Source Item Number: 523 
Description  
This variable is the behavior code from The International Classification of Diseases for Oncology, Third 
Edition (ICD-O-3) for the primary tumor being reported. With the updates and implementation of ICD-O, 
some histologies changed from malignant behavior to benign or borderline malignancy and vice versa. 
This Behavior Recode variable takes those changes into consideration.  
“Malignant” indicates a histology whose behavior did not change. “Only malignant in ICD-O-3” indicates 
histologies whose behavior changed to malignant in edition ICD-O-3. Additional changes to histologic 
behavior were made effective with cases diagnosed in 2010 and later; new histologies were added, while 
the behavior of others changed (primarily affecting hematopoetic malignancies). “Only malignant 2010+” 
limits the analysis to those histologies. 
Considerations for use  
• This database includes cases with invasive (malignant) and in situ behavior, benign/borderline 
behavior for brain/CNS cases diagnosed in 2004 and forward are also included. Caution should be 
used to select the correct behavior for analyses. Malignant behavior (including “Malignant”, “Only 
malignant in ICD-O-3”, and “Only malignant 2010+”categories) is the default selection for cases in this 
database in SEER*Stat. If necessary for the analysis, “Only malignant in ICD-O-3” or “Only malignant 
2010+” may be selected to further restrict case selection. If an analysis requires cases with in situ 
behavior, the “Malignant Only” selection should be unchecked on the “Selection” tab. 
• Behavior code ICD-O-3 is required for cancer cases diagnosed on or after January 1, 2001. Statistics 
generated from the database using this behavior code variable are comparable to the methodology 
used to generate the USCS official federal cancer statistics. 
• For more information, please see SEER coding manual at http://seer.cancer.gov/icd-o-3. 
Values Frequency  Percentage 
Benign 399,639 2.0% 
Borderline malignancy 40,816 0.2% 
In situ 1,332,496 6.7% 
Malignant 17,884,739 89.7% 
Only malignant in ICD-O-3 271,179 1.4% 
Only malignant 2010+ 11,429 0.1% 
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SEER*Stat Item Name: Merged Summary Stage 2000 
Source of Standard: NPCR 
Source Item Name: Combined from Derived SS2000 and SEER Summary Stage 2000 
Source Item Number: Derived from NAACCR 3020 and 759 
Description  
This is a merged stage variable created using two other variables: “SEER Summary Stage 2000,” which 
records stage from diagnosis years 2001–2003, and “Derived SS2000,” which records stage from 
diagnostic years 2004–2013. This stage variable can be used for diagnosis years 2001–2013.  
Considerations for use  
• The coding logic for this merged variable is: 
 If a case was diagnosed between 2001 and 2003, the Summary Stage 2000 variable value was 
used.  
 If a case was diagnosed between 2004 and 2013, then the Derived Summary Stage 2000 (Derived 
SS2000) variable was used.  
 If the Derived Summary Stage 2000 variable was blank and a valid value was available for the 
Summary Stage 2000 variable, that value was used to populate the merged variable. For example, 
if the case was diagnosed in 2013 and Derived Summary Stage was blank, but Summary Stage 
had a value of local, then the merged variable was coded as local stage. Otherwise, the merged 
variable would be left blank. 
• For more information about SEER Summary Stage 2000 and Derived SS2000 variables, please 
review https://cancerstaging.org/cstage/Pages/default.aspx. 
Values Frequency  Percentage 
In situ 1,650,415 ^1 
Localized only 8,212,144 ^1 
Regional, direct extension only 1,326,534 ^1 
Regional, regional lymph nodes only 1,408,471 ^1 
Regional, direct extension and regional lymph nodes 826,850 ^1 
Regional, NOS 208,227 ^1 
Distant site(s)/node(s) involved 4,312,960 ^1 
Not applicable 440,170 ^1 
Unknown/unstaged/unspecified- 1,554,526 ^1 
Blank(s) ^2 ^2 
1 Values are not reported due to the need for complementary cell suppression. 
2 Counts of fewer than 16 cases and the corresponding percentages are suppressed.   
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SEER*Stat Item Name: Laterality 
Source of Standard: NAACCR 
Source Item Name: Laterality at Diagnosis (SEER) 
Source Item Number: 410 
Description  
This variable identifies the side of a paired organ, or the side of the body on which the reportable tumor 
originated. This applies to the primary site only.  
Considerations for use  
For more information, please see: 
• FORDS at https://www.facs.org/quality-programs/cancer/ncdb/registrymanuals/cocmanuals  
• SEER coding manuals http://seer.cancer.gov/tools/codingmanuals/historical.html 
Values Frequency  Percentage 
Not a paired site 11,056,621 ^1 
Right - origin of primary 4,297,487 ^1 
Left - origin of primary 3,972,513 ^1 
Only one side - side unspecified 42,241 ^1 
Bilateral, single primary 157,689 ^1 
Paired site: midline tumor 29,787 ^1 
Paired site, but no information concerning laterality 383,959 ^1 
Invalid Value(s) ^2 ^2 
1 Values are not reported due to the need for complementary cell suppression. 
2 Counts of fewer than 16 cases and the corresponding percentages are suppressed. 
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SEER*Stat Item Name: Sequence Number – Central 
Source of Standard: NAACCR 
Source Item Name: Sequence Number – Central Revised 
Source Item Number: 380 
Description  
This variable indicates the sequence of all reportable neoplasms over the patient’s lifetime.  
Considerations for use  
• The sequence number may change over the patient’s lifetime. If the patient was diagnosed with a 
single reportable neoplasm, and later diagnosed with a second reportable neoplasm, the sequence 
code for the first neoplasm changes from 00 to 01. A central registry may find that a patient with one or 
more known neoplasms had an earlier reportable neoplasm that had been unknown to the registry. 
Typically, a re-evaluation of all related sequence numbers is required whenever an additional 
neoplasm is identified.  
• Standards define which neoplasms are reportable. Please see the SEER list at 
https://seer.cancer.gov/tools/casefinding/. It is assumed that these standards are the minimum 
definition of reportability. Individual central cancer registries may define additional neoplasms as 
reportable. Variability of assigning sequence numbers over time may exist for different registries, 
which may impact the coding of this variable.  
• Because the time period of Sequence Number is a person’s lifetime, reportable neoplasms not 
included in the central registry (those that occur outside the registry catchment area or before the 
reference date) also are allotted a sequence number. For example, a registry may contain a single 
record for a patient with a sequence number of 02 because the first reportable neoplasm preceded the 
central registry’s reference date. 
• If two or more reportable neoplasms are diagnosed at the same time, the lowest sequence number is 
assigned to the diagnosis with the worst prognosis. If no difference in prognosis is evident, the 
decision is arbitrary.  
• Reportable non-malignant tumors diagnosed on or after January 1, 2004 are represented by sequence 
numbers labeled as “…state registry-defined neoplasm”. Timing rules for sequencing these neoplasms 
are the same as timing rules for sequencing required in situ or invasive neoplasms.  
• The 2007 Multiple Primary and Histology Coding Rules may also affect the sequence number. For 
more information, please see https://seer.cancer.gov/tools/mphrules/mphrules_instructions.pdf. 
• For more information, please see the SEER coding manual at 
https://seer.cancer.gov/tools/codingmanuals/historical.html. 
Values Frequency  Percentage 
One primary only 14,597,728 ^1 
1st of 2 or more primaries 1,575,507 ^1 
2nd of 2 or more primaries 2,777,093 ^1 
3rd of 3 or more primaries 451,694 ^1 
4th of 4 or more primaries 75,922 ^1 
5th of 5 or more primaries 14,789 ^1 
6th or more primaries2 6,695 ^1 
Only one state registry-defined neoplasm 422,638 ^1 
1st of 2 or more state registry-defined neoplasms 7,862 ^1 
2nd of 2 or more state registry-defined neoplasms 8,962 ^1 
3rd of 3 or more state registry-defined neoplasms 592 ^1 
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Values Frequency  Percentage 
4th of 4 or more state registry-defined neoplasms 146 ^1 
5th of 5 or more state registry-defined neoplasms 74 ^1 
6th or more state registry-defined neoplasms1 30 ^1 
Carcinoma in situ of the Cervix diagnosed 1/1/1996 or later ^3 ^3 
Unknown sequence number - federally required in situ or malignant tumors 114 ^1 
Unknown sequence number - state registry-defined neoplasms 280 ^1 
1 Values are not reported due to the need for complementary cell suppression.  
2 Subsequent primaries (7 or higher) were collapsed into this category. 
3 Counts of fewer than 16 cases and the corresponding percentages are suppressed. 
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SEER*Stat Item Name: Month of Diagnosis 
Source of Standard: NAACCR 
Source Item Name: Derived from “Date of initial diagnosis (CoC)” 
Source Item Number: 390 
Description  
This variable is derived from “date of initial diagnosis,” which is the date of initial diagnosis by a 
recognized medical practitioner for the cancer being reported, whether clinically or microscopically 
confirmed. 
Considerations for use  
The day of diagnosis is not provided as an additional confidentiality measure.  
Values Frequency  Percentage 
January 1,762,231 8.8% 
February 1,554,340 7.8% 
March 1,702,487 8.5% 
April 1,665,761 8.4% 
May 1,684,518 8.4% 
June 1,714,900 8.6% 
July 1,629,758 8.2% 
August 1,687,981 8.5% 
September 1,595,031 8.0% 
October 1,706,012 8.6% 
November 1,568,364 7.9% 
December 1,532,169 7.7% 
Blank(s) 136,746 0.7% 
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SEER*Stat Item Name: Type of Reporting Source 
Source of Standard: NAACCR 
Source Item Name: Type of reporting source 
Source Item Number: 500 
Description  
This variable codes the source documents used to abstract the majority of information on the tumor being 
reported. This may not be the source of original case finding (for example, if a case is identified through a 
pathology laboratory report review and all source documents used to abstract the case are from the 
physician’s office, code 4 is assigned).  
Considerations for use  







Hospital inpatient/outpatient or clinic 
3 Laboratory only (hospital or private) 
4         Physician’s office/private medical practitioner (local medical doctor)  
5 Nursing/convalescent home/hospice  
Since there was no code specific to radiation treatment facilities or ambulatory surgery centers, they were 
coded as either 1 or 4. 
• For cancers diagnosed in 2006 and later, the following codes were added to allow identification of cases 
reported by radiation treatment centers, medical oncology clinics, and other hospital outpatient units/surgery 
centers. 
Code Definition 
2 Radiation treatment centers, medical oncology clinics 
8 Other hospital outpatient units/surgery centers 
• Cases were coded in the following priority order: 1, 2, 8, 4, 3, 5. This reflects the addition of codes 2 and 8 and 
prioritizes laboratory reports over nursing home reports. The source facilities included in the previous code 1 
(hospital inpatient and outpatient) are split between codes 1, 2, and 8. 
Values Frequency  Percentage 
Hospital inpatient/outpatient or clinic 17,500,897 87.8% 
Radiation treatment or medical oncology center (2006+) 374,926 1.9% 
Laboratory only (hospital or private) 494,329 2.5% 
Physician’s office/private medical practitioner (LMD) 864,068 4.3% 
Nursing/convalescent home/hospice 25,335 0.1% 
Other hospital outpatient unit or surgery center (2006+) 680,743 3.4% 
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Additional resources  
• NPCR www.cdc.gov/cancer/npcr/ 
• USCS Publication Standard www.cdc.gov/cancer/npcr/uscs/technical_notes/criteria.htm 
• NAACCR www.naaccr.org/ 
• NAACCR data dictionary www.naaccr.org/StandardsandRegistryOperations/VolumeII.aspx 
• American College of Surgeons Commission on Cancer (CoC) Registry Manuals: Facility Oncology Registry 
Data Standards (FORDS) or Registry Operations and Data Standards (ROADS) www.facs.org/quality-
programs/cancer/ncdb/registrymanuals/cocmanuals 
• SEER https://seer.cancer.gov 
• SEER site recode ICD-O-3/WHO 2008 https://seer.cancer.gov/siterecode/icdo3_dwhoheme/index.html 
• ICCC site recode ICD-O-3/WHO 2008 https://seer.cancer.gov/iccc/iccc-who2008.html 
• AYA site recode ICD-O-3/WHO 2008 https://seer.cancer.gov/ayarecode/ 
• Lymphoma subtype recode ICD-O-3/WHO 2008 https://seer.cancer.gov/lymphomarecode/ 
• ICD-O-3 http://apps.who.int/iris/bitstream/10665/96612/1/9789241548496_eng.pdf 
• Collaborative Staging Manual http://cancerstaging.org/cstage/manuals.html 
• Census www.census.gov 
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Abbreviations  
AI/AN  American Indian / Alaska Native 
A/PI  Asians and Pacific Islanders 
AYA  Adolescent and young adult 
CCR  Central cancer registry 
CNS  Central nervous system 
CoC  Commission on Cancer 
CS  Collaborative Stage 
Dx  Diagnosis 
ICCC  International Classification of Childhood Cancer 
ICD-O-3  International Classification of Diseases for Oncology, Third Edition 
NAACCR  North American Association of Central Cancer Registries 
NAPIIA NAACCR  Asian Pacific Islander Identification Algorithm  
NHIA NAACCR  Hispanic Identification Algorithm 
NOS  Not otherwise specified 
NPCR  National Program of Cancer Registries 
SEER  Surveillance, Epidemiology, and End Results 
SS  Summary Stage 
USCS  United States Cancer Statistics 
WHO  World Health Organization 
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Appendix A. Indian Health Services (IHS) Linkage Schedule 
All NPCR-funded registries link with the Indian Health Service every five years. The most recent linkage year was 
2016. 
All state central cancer registries with Contract Health Service Delivery Area (CHSDA) counties link with the 
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